292 related articles for article (PubMed ID: 33297719)
1. Ulipristal Acetate for Treatment of Premenstrual Dysphoric Disorder: A Proof-of-Concept Randomized Controlled Trial.
Comasco E; Kopp Kallner H; Bixo M; Hirschberg AL; Nyback S; de Grauw H; Epperson CN; Sundström-Poromaa I
Am J Psychiatry; 2021 Mar; 178(3):256-265. PubMed ID: 33297719
[TBL] [Abstract][Full Text] [Related]
2. Treatment of premenstrual dysphoric disorder with the GABA
Bixo M; Ekberg K; Poromaa IS; Hirschberg AL; Jonasson AF; Andréen L; Timby E; Wulff M; Ehrenborg A; Bäckström T
Psychoneuroendocrinology; 2017 Jun; 80():46-55. PubMed ID: 28319848
[TBL] [Abstract][Full Text] [Related]
3. Symptom-Onset Dosing of Sertraline for the Treatment of Premenstrual Dysphoric Disorder: A Randomized Clinical Trial.
Yonkers KA; Kornstein SG; Gueorguieva R; Merry B; Van Steenburgh K; Altemus M
JAMA Psychiatry; 2015 Oct; 72(10):1037-44. PubMed ID: 26351969
[TBL] [Abstract][Full Text] [Related]
4. A randomized, double-blind study on efficacy and safety of sepranolone in premenstrual dysphoric disorder.
Bäckström T; Ekberg K; Hirschberg AL; Bixo M; Epperson CN; Briggs P; Panay N; O'Brien S
Psychoneuroendocrinology; 2021 Nov; 133():105426. PubMed ID: 34597899
[TBL] [Abstract][Full Text] [Related]
5. Weekly luteal-phase dosing with enteric-coated fluoxetine 90 mg in premenstrual dysphoric disorder: a randomized, double-blind, placebo-controlled clinical trial.
Miner C; Brown E; McCray S; Gonzales J; Wohlreich M
Clin Ther; 2002 Mar; 24(3):417-33. PubMed ID: 11952025
[TBL] [Abstract][Full Text] [Related]
6. Grey matter morphology in women with premenstrual dysphoric disorder treated with a selective progesterone receptor modulator.
Kaltsouni E; Dubol M; Wikström J; Lanzenberger R; Sundström-Poromaa I; Comasco E
Eur Neuropsychopharmacol; 2022 Dec; 65():35-43. PubMed ID: 36343426
[TBL] [Abstract][Full Text] [Related]
7. Effects of GABA active steroids in the female brain with a focus on the premenstrual dysphoric disorder.
Bixo M; Johansson M; Timby E; Michalski L; Bäckström T
J Neuroendocrinol; 2018 Feb; 30(2):. PubMed ID: 29072794
[TBL] [Abstract][Full Text] [Related]
8. Brain reactivity during aggressive response in women with premenstrual dysphoric disorder treated with a selective progesterone receptor modulator.
Kaltsouni E; Fisher PM; Dubol M; Hustad S; Lanzenberger R; Frokjaer VG; Wikström J; Comasco E; Sundström-Poromaa I
Neuropsychopharmacology; 2021 Jul; 46(8):1460-1467. PubMed ID: 33927343
[TBL] [Abstract][Full Text] [Related]
9. A lecithin phosphatidylserine and phosphatidic acid complex (PAS) reduces symptoms of the premenstrual syndrome (PMS): Results of a randomized, placebo-controlled, double-blind clinical trial.
Schmidt K; Weber N; Steiner M; Meyer N; Dubberke A; Rutenberg D; Hellhammer J
Clin Nutr ESPEN; 2018 Apr; 24():22-30. PubMed ID: 29576358
[TBL] [Abstract][Full Text] [Related]
10. 5α-Reductase Inhibition Prevents the Luteal Phase Increase in Plasma Allopregnanolone Levels and Mitigates Symptoms in Women with Premenstrual Dysphoric Disorder.
Martinez PE; Rubinow DR; Nieman LK; Koziol DE; Morrow AL; Schiller CE; Cintron D; Thompson KD; Khine KK; Schmidt PJ
Neuropsychopharmacology; 2016 Mar; 41(4):1093-102. PubMed ID: 26272051
[TBL] [Abstract][Full Text] [Related]
11. Premenstrual Dysphoric Disorder Symptoms Following Ovarian Suppression: Triggered by Change in Ovarian Steroid Levels But Not Continuous Stable Levels.
Schmidt PJ; Martinez PE; Nieman LK; Koziol DE; Thompson KD; Schenkel L; Wakim PG; Rubinow DR
Am J Psychiatry; 2017 Oct; 174(10):980-989. PubMed ID: 28427285
[TBL] [Abstract][Full Text] [Related]
12. [Efficacy and safety of a combined oral contraceptive containing drospirenone 3 mg and ethinylestradiol 20 µg in the treatment of premenstrual dysphoric disorder: a randomized, double blind placebo-controlled study].
Fu Y; Mi W; Li L; Zhang H; Wang J; Cheng W; Sun L; Li L; Xie S; Zhang J
Zhonghua Fu Chan Ke Za Zhi; 2014 Jul; 49(7):506-9. PubMed ID: 25327732
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of a unique oral contraceptive in the treatment of premenstrual dysphoric disorder.
Freeman EW; Kroll R; Rapkin A; Pearlstein T; Brown C; Parsey K; Zhang P; Patel H; Foegh M;
J Womens Health Gend Based Med; 2001; 10(6):561-9. PubMed ID: 11559453
[TBL] [Abstract][Full Text] [Related]
14. Continuous oral levonorgestrel/ethinyl estradiol for treating premenstrual dysphoric disorder.
Halbreich U; Freeman EW; Rapkin AJ; Cohen LS; Grubb GS; Bergeron R; Smith L; Mirkin S; Constantine GD
Contraception; 2012 Jan; 85(1):19-27. PubMed ID: 22067793
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of a unique oral contraceptive (Yasmin) in the management of premenstrual dysphoric disorder.
Freeman EW
Eur J Contracept Reprod Health Care; 2002 Dec; 7 Suppl 3():27-34; discussion 42-3. PubMed ID: 12659404
[TBL] [Abstract][Full Text] [Related]
16. Does Symptom-Onset Treatment With Sertraline Improve Functional Impairment for Individuals With Premenstrual Dysphoric Disorder?: A Randomized Controlled Trial.
Yonkers KA; Altemus M; Gilstad-Hayden K; Kornstein SG; Gueorguieva R
J Clin Psychopharmacol; 2023 Jul-Aug 01; 43(4):320-325. PubMed ID: 37212651
[TBL] [Abstract][Full Text] [Related]
17. New Pharmacological Approaches to the Management of Premenstrual Dysphoric Disorder.
Sundström-Poromaa I; Comasco E
CNS Drugs; 2023 May; 37(5):371-379. PubMed ID: 37171547
[TBL] [Abstract][Full Text] [Related]
18. [Premenstrual syndrome and premenstrual dysphoric disorder].
Kovács Z; Hegyi G; Szőke H
Orv Hetil; 2022 Jun; 163(26):1023-1031. PubMed ID: 35895486
[TBL] [Abstract][Full Text] [Related]
19. Association between Generalized Anxiety Disorder and Premenstrual Dysphoric Disorder in a Diagnostic Interviewing Study.
Yen JY; Lin PC; Huang MF; Chou WP; Long CY; Ko CH
Int J Environ Res Public Health; 2020 Feb; 17(3):. PubMed ID: 32033286
[TBL] [Abstract][Full Text] [Related]
20. Limbic self-neuromodulation as a novel treatment option for emotional dysregulation in premenstrual dysphoric disorder (PMDD); a proof-of-concept study.
Tene O; Bleich Cohen M; Helpman L; Fine N; Halevy A; Goldway N; Perry D; Bary P; Aisenberg Romano G; Ben-Zion Z; Hendler T; Bloch M
Psychiatry Clin Neurosci; 2023 Oct; 77(10):550-558. PubMed ID: 37354437
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
